HeartLight® X3 System For The Treatment Of Atrial Fibrillation Receives CE Mark Approval

UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care

The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round.

Jon Hopkins New Senior Vice President-Chief Development Officer of Legion Healthcare Partners

Over the past 23 years, Jon has held various positions at Varian Medical Systems including Director of Sales, Americas West & Latin America, Varian Proton Solutions and prior Director of Worldwide Sales, Varian Particle Therapy.

Sinan Batman Appointed CTO of TeraRecon

Batman brings rich industry experience to TeraRecon, including Chief Engineer at Carestream/Kodak Health Group, where he defined the vision for image-centric workflow information systems.

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.

The HeartLight X3 System is a third generation technology building upon the advanced features of the HeartLight Endoscopic Ablation System, which performs pulmonary vein isolation (PVI) using laser energy to create lines of scar tissue to block the abnormal electrical pathways that cause AFib. Using direct tissue visualization, titratable laser energy, and compliant balloon technology, the HeartLight X3 System’s unique RAPID mode leverages a precise motor control system that enables uninterrupted, high-speed, circumferential lesion creation under direct control of the physician resulting in consistently reduced procedure times.

More than 33 million patients worldwide suffer from AFib, the most common type of cardiac rhythm disorder.1, 2 In Europe alone, it is estimated that the number of patients will rise to 14-17 million by 20303.

“Our clinical results using the HeartLight X3 System have been outstanding, with unprecedented treatment speed and precise lesion creation,” said Boris Schmidt, MD an investigator in the pivotal confirmatory trial at Cardioangiologisches Centrum Bethanien in Frankfurt, Germany. “Based on our experience with the device, we feel confident that the HeartLight X3 System is poised to change the way AFib ablation is performed in Europe.”

In the pivotal confirmatory evaluation of 60 patients, the HeartLight X3 System consistently achieved very rapid PVI, in as few as three minutes for a single vein. The trial also found that the System has the potential to complete all required ablations in less than 20 minutes.

Commercial introduction of the HeartLight X3 System in Europe will begin immediately. Current users of the HeartLight platform may start using HeartLight X3 technology after a simple upgrade.

“We are eager to begin the commercialization of the breakthrough HeartLight X3 System in the European market,” said Burke T. Barrett, President and Chief Operating Officer at CardioFocus. “In partnership with our physician users, we are committed to continued innovation and delivering the best treatment modalities in the AFib ablation space.”

The HeartLight X3 System is only approved for use in Europe. The HeartLight X3 System is not available for sale in the U.S.


References

1 Chugh SS, Havmoeller R, Narayanan K, et al.; Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. Circulation. 2014 Feb 25;129(8):837-47.

Chugh SS, Havmoeller R, Narayanan K, et al.; Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. Circulation. 2014 Feb 25;129(8):837-47.

3 Zoni-Berisso, Massimo et al. “Epidemiology of Atrial Fibrillation: European Perspective.” Clinical Epidemiology 6 (2014): 213–220. PMC. Web. 25 July 2017.

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles